



IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

NASDAQ: **IDYA**

March 2024

IDEAYA Highlights

Breakthrough Science on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships with GlaxoSmithKline¹, including ~\$2 billion in potential cash milestones, Pfizer² and Amgen³

Strong Balance Sheet of ~\$975 million⁴ with capital efficient model

Analyst Coverage by BTIG, Capital One, Citi, Goldman Sachs, Jefferies, JP Morgan, Leerink, Oppenheimer, RBC, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements
- (3) Amgen Clinical Trial Collaboration and Supply Agreement
- (4) Includes aggregate of \$632.6M cash, cash equivalents and marketable securities as of December 31, 2023, plus pro forma \$342.3M estimated net proceeds from sales of common stock through at-the-market offerings in January 2024